Dynamic economies of scope in the pharmaceutical industry

Industrial and Corporate Change

Volumn 7, Issue 3, 1998, Pages 501-517

  Kurdas, Chidem ^a  

^a Medical Economics Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001265064     PISSN: 09606491     EISSN: None     Source Type: Journal    
DOI: 10.1093/icc/7.3.501     Document Type: Article

References (55)

1. Achilladelis, B. (1993), 'The Dynamics of Technological Innovation: The Sector of Antibacterial Medicines,' Research Policy, 22, 279-308.
2. Arora, A. and A. Gambardella (1990), 'Complementarity and External Linkages: The Strategies of the Large Firms in Biotechnology,'Journal of Industrial Economics, XXXVIII, 361-379.
3. Baldwin, C. Y and K. B. Clark (1994), 'Capital-budgeting Systems and Capabilities Investments in US companies after the Second World War,' Business History Review, 68, 73-109.
4. Bindra, J. and D. Lednicer (1982), Chronicles of Drug Discovery, Vol. 1. Wiley: New York.
5. Chandler, A. D., Jr (1961) Strategy and Structure. Chapters in the History of the Industrial Enterprise, reprinted in 1990 with a new introduction. MIT Press: Cambridge, MA.
6. Chandler, A. D., Jr (1990), Scale and Scope. The Dynamics of Industrial Capitalism. Belknap Press of Harvard University Press: Cambridge, MA.
7. Chandler, A. D., Jr (1992), 'Organizational Capabilities and the Economic History of the Industrial Enterprise,' Journal of Economic Perspectives, 6(3).
8. Chandler, A. D., Jr (1994), 'The Competitive Performance of US Industrial Enterprises since the Second World War,' Business History Review, 68, 1-72.
9. Comanor, W S. (1986), 'The Political Economy of the Pharmaceutical Industry,' Journal of Economic Literature, XXIV (3).
10. Cornes, R. and T. Sandler (1986), The Theory of Externalities, Public Goods, and Club Goods. Cambridge University Press: Cambridge.
11. Dosi, G. (1982), 'Technological Paradigms and Technological Trajectories. A Suggested Interpretation of the Determinants and Directions of Technical Change,' Research Policy, 11, 147-162.
12. Dosi, G. (1988a), 'Sources, Procedures, and Microeconomic Effects of Innovation,' Journal of Economic Literature, XXVI, 1120-1171.
13. Dosi, G. (1988b), The Nature of the Innovative Process,' in G. Dosi et al. (eds), Technical Change and Economic Theory, pp. 221-238. Pinter: London.
14. Freeman, C. and C. Perez (1988), 'Structural Crises of Adjustment, Business Cycles and Investment Behaviour,' in G. Dosi et al. (eds.), Technical Change and Economic Theory, pp. 38-66. Pinter: London.
15. Freudenheim, M. (1996), 'Two Drug Makers Linking to find Winning Products,' New York Times, March 8, D1.
16. Gambardella, A. (1992), 'Competitive Advantages from In-house Scientific Research: The US Pharmaceutical Industry in the 1980s,' Research Policy, 21, 391-407.
17. Gitman, L. J. and V. A. Mercurio (1982), 'Cost of Capital Techniques Used by Major US Firms: Survey and Analysis of Fortune's 1000,' Journal of Financial Management, 11, 21-29.
18. Gomulka, S. (1990), The Theory of Technological Change and Economic Growth. Routledge: London.
19. Grabowski, H. and J. Vernon (1994), 'Innovation and Structural Change in Pharmaceuticals and Biotechnology,' Industrial and Corporate Change, 3, 435-450.
20. Grabowski, H. and J. Vernon (1990), 'A New Look at the Returns and Risks to Pharmaceutical R&D,' Management Science, 36, 804-821.
21. Henderson, R. M. (1994), 'The Evolution of Integrative Capability: Innovation in Cardiovascular Drug Discovery,' Industrial and Corporate Change, 3, 607-630.
22. Henderson, R. M. and K. B. Clark (1990), 'Architectural Innovation: The Reconfiguration of Existing Product Technologies and the Failure of Established Firms,' Administrative Science Quarterly, 35, 9-30.
23. Hirshleifer, J. and J. G. Riley (1992), The Analytics of Uncertainty and Information. Cambridge University Press: New York.
24. Klevorick, A., R. Levin, R. Nelson and S. Winter (1995), On the Sources and Significance of Interindustry Differences in Technological Opportunities,' Research Policy, 24, 185-205.
25. Kuran, T. (1988), 'The Tenacious Past: Theories of Personal and Collective Conservatism,' Journal of Economic Behavior and Organization, 10, 143-171.
26. Kurdas, C. (1994), Theories of Technical Change and Investment. Riches and Rationality. St Martin's Press: New York/Macmillan: London.
27. Langlois, R. N. (1992), The Capabilities of Industrial Capitalism,' Critical Review, 5, 513-530.
28. Langlois, R. N. (1986), 'Rationality, Institutions and Explanation,' in R. Langlois (ed.), Economics as a Process: Essays in the New Institutional Economics, pp. 225-255. Cambridge University Press: Cambridge.
29. (1991), Equilibrium and Evolution. St Martin's Press: New York.
30. Loasby, B. J. (1986), Organization, Competition, and the Growth of Knowledge,' in R. Langlois (ed.), Economics as a Process: Essays in the New Institutional Economics, pp. 41-58. Cambridge University Press: Cambridge.
31. Mokyr, J. (1994), 'Cardwell's Law and the Political Economy of Technological Progress,' Research Policy, 23, 561-574.
32. Nelson, R. (1988), 'Modelling Connections in the Cross Section Between Technical Progress and R&D Intensity,' Rand Journal of Economics, 19, 478-485.
33. Nelson, R. and S. Winter (1982), An Evolutionary Theory of Economic Change. Belknap Press of Harvard University Press: Cambridge, MA.
34. Orsenigo, L. (1989), The Emergence of Biotechnology: Institutions and Markets in Industrial Innovation. St Martin's Press: New York
35. Pharmaceutical Manufacturers' Association, Statistical Fact Book (various issues).
36. Pharmaceutical Manufacturers' Association, New Drug Approvals (various issues).
37. Pisano, G. E (1991), 'The Governance of Innovation: Vertical Integration and Collaborative Arrangements in the Biotechnology Industry,' Research Policy, 20, 237-249.
38. Pisano, G. P. (1990), 'The R&D Boundaries of the Firm: An Empirical Analysis,' Administrative Science Quarterly, 35, 153-176.
39. Rosenberg, N. (1994), Exploring the Black Box: Technology, Economics, and History. Cambridge University Press: Cambridge.
40. Rosenberg, N. (1976), Perspectives on Technology. M. E. Sharpe: Armonk, NY.
41. Scherer, F. M. (1993), 'Pricing, Profits and Technological Progress in the Pharmaceutical Industry, Journal of Economic Perspectives, 7, 97-115.
42. Seligman, M. (1993), What You Can Change and What You Can't. Alfred A. Knopf: New York.
43. Stevenson, R. W. (1995), 'Glaxo Offers $14 Billion for Wellcome,' New York Times, January 24, D1.
44. Teece, D. (1980) 'Economies of Scope and the Scope of the Enterprise,' Journal of Economic Behavior and Organization, 1, 223-247.
45. Teece, D. (1982) 'Towards an Economic Theory of the Multiproduct Firm,' Journal of Economic Behavior and Organization, 3, 39-63.
46. Teece, D. (1988), 'Technological Change and the Nature of the Firm,' in G. Dosi et al. (eds), Tichnical Change and Economic Theory, pp. 256-281. Pinter: London.
47. Teece, D. and G. Pisano (1994), 'The Dynamic Capabilities of Firms: An Introduction,' Industrial and Corporate Change, 3, 537-556.
48. Teece, D., R. Rumelt, G. Dosi and S. Winter (1994), 'Understanding Corporate Coherence: Theory and Evidence,' Journal of Economic Behavior and Organization, 23, 1-30. Thomas, L. G. (1994), 'Implicit Industrial Policy: The Triumph of Britain and the Failure of France in Global Pharmaceuticals,' Industrialand Corporate Change, 3, 451-490.
49. Teece, D., R. Rumelt, G. Dosi and S. Winter (1994), 'Understanding Corporate Coherence: Theory and Evidence,' Journal of Economic Behavior and Organization, 23, 1-30. Thomas, L. G. (1994), 'Implicit Industrial Policy: The Triumph of Britain and the Failure of France in Global Pharmaceuticals,' Industrialand Corporate Change, 3, 451-490.
50. Thomas, L. G. (1990), 'Regulation and Firm Size: FDA Impacts on Innovation,' Rand Journal of Economics, 21, 497-517.
51. Tushman, M. and P. Anderson (1986), 'Technological Discontinuities and Organizational Environments,' Administrative Science Quarterly, 31, 439-65.
52. US Congress, Office of Technology Assessment (1993), Pharmaceutical R&D: Costs, Risks and Rewards. US Government Printing Office, Washington, DC.
53. Williamson, O. E. (1988), 'The Logic of Economic OrgAinzation,' Journal of Law, Economics and Organization, 4, 65-94.
54. Williamson, O. E. (1985), The Economic Institutions of Capitalism. Free Press: New York.
55. Winter, S. G. (1988), On Coase, Competence, and the Corporation,' Journal of Law, Economics, and Organization, 4, 163-180.